Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2025 08:05 ET | Source: Fortress Biotech, Inc.

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing

Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange...